IBRX?...note for shorters....don't short a FDA approved drug

Original Reddit post

Author argues IBRX is an early positioning setup because Anktiva is FDA-approved and activates NK cells, ahead of oncology biotech peers.

IBRX — LONG The author argues ImmunoBio (IBRX) is an early positioning setup because Anktiva activates NK cells, a proven immunology pathway, and is already FDA-approved and in patients. This approval status differentiates IBRX from oncology biotech peers still in development, and multiple cancer indications are on the table. The author frames this as a name that gets noticed after the narrative shifts, implying a catalyst-driven re-rating. No specific risk is stated.

Anktiva activates NK cells — a proven immunology pathway — and it’s already FDA-approved and in patients. That puts IBRX miles ahead of the usual oncology biotech crowd still selling slides.